| Date | Title | Description |
| 10.03.2025 | Cambridge Innovation Capital: £100 Million Opportunity Fund Closed | Cambridge Innovation Capital (CIC), a leading venture capital firm embedded in the Cambridge ecosystem, announced it has launched a new £100 million Opportunity Fund – which is anchored by Aviva Investors and British Patient Capital – to in... |
| 24.02.2025 | Cambridge Innovation Capital launches £100M Fund for deeptech and life sciences | Cambridge Innovation Capital (CIC) has today launched a new £100 million Opportunity Fund to invest in growth stage deep tech and life sciences companies.
With up to £20 million per investment into later-stage rounds of deep tech and life s... |
| 24.02.2025 | Cambridge Innovation Capital launches £100m Opportunity Fund | Aviva Investors and British Patient Capital lead investment into new growth fund addressing the UK’s scale-up funding gap.
24 February 2025, Cambridge, UK — Cambridge Innovation Capital (CIC), the leading venture capital firm embedded in th... |
| 15.09.2022 | Find your next job at Cambridge Network’s Virtual Jobs & Careers Fair – still time to sign up | Calling all jobseekers! Don't miss Cambridge Network's Virtual Jobs & Careers Fair taking place on Friday 16th September 2022.
This FREE online event (from 11am to 4pm allows you to dip in and out as you wish) and will include the lates... |
| 01.08.2022 | Slone Partners Places Thomas Schlumpberger as Chief Executive Officer at Nanomix | “Thomas Schlumpberger is an experienced and admired leader in the POC diagnostics field where he has achieved extraordinary success in every management role,” said Slone Partners President Tara Kochis.
SOUTH RIDING, Va. (PRWEB) August 01, 2... |
| 29.09.2021 | Entrepreneurial pathways to impact: spinning-out your research | Entrepreneurial pathways to impact: spinning-out your research
Hosted by Cambridge Innovation Capital in partnership with Cambridge Enterprise
Supported by Babraham Institute, Wellcome Sanger Institute, Start Codon and Deeptech Labs
Registe... |
| 18.06.2021 | NeoGenomics completes Inivata acquisition | NeoGenomics completes Inivata acquisition
Combining best-in-class liquid biopsy technology with leading community oncology platform
Acquisition establishes NeoGenomics as a technology leader in the minimal residual disease (MRD) testing mar... |
| 25.05.2021 | Inivata Announces Collaboration with F-star Therapeutics for the use of RaDaR™ Assay | Inivata Announces Collaboration with F-star Therapeutics for the use of RaDaR™ Assay
RaDaR ctDNA liquid biopsy to monitor response of late-stage solid tumors to treatment
Inivata, a leader in liquid biopsy, today announced a collaboration w... |
| 05.05.2021 | Cambridge Innovation Capital announces acquisition of portfolio company Inivata | Cambridge Innovation Capital announces acquisition of portfolio company Inivata
Cambridge Innovation Capital (CIC), the venture capital investor focused on IP-rich deep technology and life science businesses in the Cambridge ecosystem, toda... |
| 05.05.2021 | US giant swallows rest of Inivata in $415m acquisition | US giant swallows rest of Inivata in $415m acquisition
Business Weekly article | By Tony Quested
NASDAQ powerhouse NeoGenomics Inc has exercised its right to hoover up the whole of Cambridge liquid biopsy specialist Inivata.
Having made a $... |
| 28.04.2021 | Inivata and Agendia sign agreement for commercialization of RaDaR® MRD liquid biopsy assay in breast cancer | Inivata and Agendia sign agreement for commercialization of RaDaR® MRD liquid biopsy assay in breast cancer
Agendia granted co-exclusive distribution rights for RaDaR in North America and Europe
Inivata, a leader in liquid biopsy, today ann... |
| 10.04.2021 | Inivata presents new data in support of its liquid biopsy technologies at AACR Virtual Annual Meeting 2021 | Inivata presents new data in support of its liquid biopsy technologies at AACR Virtual Annual Meeting 2021
Inivata’s RaDaR® MRD assay performed with exceptionally high sensitivity and specificity (100% MRD detection) in head and neck cancer... |
| 09.03.2021 | FDA grants breakthrough device designation for Inivata’s RaDaR™ Assay | FDA Grants Breakthrough Device Designation for Inivata’s RaDaR™ Assay
Designation will help accelerate the regulatory path of RaDaR for use in detection of MRD in early-stage cancer patients
Inivata, a leader in liquid biopsy, today announc... |
| 09.02.2021 | Inivata raises $35 million in second close of Series C financing | Inivata raises $35 million in second close of Series C financing
09-02-2021
Inivata, a leader in liquid biopsy, announced that it has raised $35 million (£25.7 million) in a second close of a Series C financing round.
The round was led by S... |
| 09.02.2021 | Inivata raises $35 million in second close of Series C financing | Inivata, a leader in liquid biopsy, announced that it has raised $35 million (£25.7 million) in a second close of a Series C financing round.
The round was led by Soleus Capital, who were joined by new investors including Janus Henderson In... |
| 04.02.2021 | Inivata Raises $35 million in Second Close of Series C Financing | Inivata Raises $35 million in Second Close of Series C Financing
Funds will accelerate clinical development of RaDaR™ minimal residual disease assay and commercialization of InVisionFirst®-Lung
Research Triangle Park, NC, USA and Cambridge,... |
| 04.02.2021 | IP GROUP PLC
IP : Inivata Ltd - Inivata Raises $35 million in Second Close of Series C Financing | Funds will accelerate clinical development of RaDaR™ minimal residual disease assay and commercialization of InVisionFirst®-Lung
Inivata, a leader in liquid biopsy, today announces it has raised $35 million (£25.7 million) in a second close... |
| 04.02.2021 | IP : Inivata Ltd - Inivata Raises $35 million in Second Close of Series C Financing | Funds will accelerate clinical development of RaDaR™ minimal residual disease assay and commercialization of InVisionFirst®-Lung
Inivata, a leader in liquid biopsy, today announces it has raised $35 million (£25.7 million) in a second close... |
| 04.02.2021 | Inivata raises $35 million in second close of Series C financing | Inivata raises $35 million in second close of Series C financing
Funds will accelerate clinical development of RaDaR™ minimal residual disease assay and commercialization of InVisionFirst®-Lung
Inivata, a leader in liquid biopsy, today anno... |
| 27.01.2021 | A year in review: Business update January 2021 | Cambridge has always been at the forefront of innovation. As the leading venture capital investor in Cambridge, CIC plays a central role in commercialising this innovation for the benefit of society. In the last year, CIC’s existing portfol... |
| 20.01.2021 | First patients tested with InVisionFirst®-Lung in EORTC sponsored Phase II NSCLC study | First patients tested with InVisionFirst®-Lung in EORTC sponsored Phase II NSCLC study
Inivata’s InVisionFirst®-Lung is being used for ctDNA testing and monitoring of patients treated with lorlatinib
Study supported by a grant from Pfizer I... |
| 18.12.2020 | Inivata’s liquid biopsy technology included in unique £10m research collaboration | Inivata’s liquid biopsy technology included in unique £10m research collaboration for early detection of lung cancer
Research Collaboration to be led by the University of Southampton and along with several major diagnostics and informatics ... |
| 26.11.2020 | Inivata Appoints Dr. Alan Schafer as Chief Technology Officer | Inivata Appoints Dr. Alan Schafer as Chief Technology Officer
Inivata, a leader in liquid biopsy, today announces the appointment of Dr. Alan Schafer as Chief Technology Officer (CTO), effective immediately. Alan will lead the development o... |
| 29.10.2020 | Inivata announces collaboration with Maverick Therapeutics for use of RaDaR™ assay | Inivata announces collaboration with Maverick Therapeutics for use of RaDaR™ assay
RaDaR ctDNA liquid biopsy test to be used to monitor patient response in Phase 1/2 study of MVC-101 in multiple tumor types
Inivata, a leader in liquid biops... |
| 22.09.2020 | Inivata Appoints Peter Collins as Chief Business Officer | Inivata Appoints Peter Collins as Chief Business Officer
Inivata, a leader in liquid biopsy, today announces the appointment of Peter Collins as Chief Business Officer, effective immediately. Peter will be responsible for leading all busine... |
| 29.06.2020 | Inivata's US commercial launch of InVisionFirst®-Lung | Inivata’s liquid biopsy test for advanced non-small cell lung cancer is now available through NeoGenomics in the US
Research Triangle Park, NC, USA and Cambridge, UK – Inivata, a leader in liquid biopsy, today announces that NeoGenomics, In... |
| 22.06.2020 | Annual results for the year ended 31 March 2020 | Expansion to 30 portfolio companies and 46% increase in net asset value, reinforcing CIC’s position as the most active series A investor in the Cambridge ecosystem
Cambridge Innovation Capital plc (CIC), the venture capital investor enablin... |
| 26.05.2020 | Inivata Announces Strategic Collaboration and Investment from NeoGenomics | NeoGenomics will commercialize Inivata’s InVisionFirst®-Lung liquid biopsy test in the United States. Equity investment in Inivata to support further development of leading liquid biopsy technology and products
Research Triangle Park, NC, U... |
| 26.05.2020 | Portfolio company Inivata announces collaboration and investment from NeoGenomics | Cambridge Innovation Capital portfolio company Inivata announces strategic collaboration and investment from NeoGenomics
Cambridge Innovation Capital (CIC), the venture capital investor enabling visionaries to build global, category-leading... |
| 26.05.2020 | CIC portfolio company Inivata announces strategic collaboration and investment from NeoGenomics | Cambridge Innovation Capital (CIC), the venture capital investor enabling visionaries to build global, category-leading companies in the Cambridge ecosystem, is pleased to note that portfolio company Inivata, a leader in liquid biopsy, has ... |
| 26.05.2020 | CIC portfolio company Inivata announces strategic collaboration and investment from NeoGenomics | CIC portfolio company Inivata announces strategic collaboration and investment from NeoGenomics
26-05-2020
Cambridge Innovation Capital (CIC), the venture capital investor enabling visionaries to build global, category-leading companies in ... |
| 24.04.2020 | Inivata launches RaDaR™ for the detection of residual disease and recurrence | Inivata, a Cambridge Innovation Capital portfolio company and a leader in liquid biopsy, announces the availability of RaDaR™, an assay for the detection and monitoring of residual disease and recurrence in the plasma samples of patients pr... |
| 24.04.2020 | Inivata launches RaDaR™ for the detection of residual disease and recurrence | Inivata launches RaDaR™ for the detection of residual disease and recurrence
24-04-2020
Inivata, a Cambridge Innovation Capital portfolio company and a leader in liquid biopsy, announces the availability of RaDaR™, an assay for the detectio... |
| 23.04.2020 | Inivata launches RaDaR™ for the detection of residual disease and recurrence | Personalized multi-tumor test provides potential new option for the rapid and sensitive identification of residual disease and clinical relapse.
Initial application in pharmaceutical clinical trial settings.
Research Triangle Park, NC, USA ... |
| 27.02.2020 | Inivata’s Nitzan Rosenfeld to Receive 2020 Cancer Researcher Award | Research Triangle Park, NC, USA and Cambridge, UK - Inivata, a leader in liquid biopsy, is pleased to announce that Dr. Nitzan Rosenfeld, Co-founder and Chief Scientific Officer at Inivata has been announced the winner of the 2020 Pezcoller... |
| 16.04.2019 | Inivata, Thermo Fisher scientific and genomics england Successfully complete first phase of study | Initial phase reveals high quality of samples through analysis using Inivata and Thermo Fisher Scientific’s liquid biopsy technologies Collection methods suitable for ctDNA analysis
Genomics England has announced today the successful comple... |
| 01.04.2019 | Term Sheet — Monday, April 1 | FACT VS. FICTION
Good morning, Term Sheet readers. I want to start today’s newsletter with an announcement that I’ll be moving to the coast of Italy to pursue my true passions of sleep and reading for pleasure. I will sincerely miss you guy... |
| 29.03.2019 | Inivata Completes $52.6M Series B Funding Round | Inivata, a leader in liquid biopsy, today announces the completion of a Series B fundraising of $52.6m (£39.8 million).
Existing investors Woodford Patient Capital Trust, IP Group, Cambridge Innovation Capital and Johnson & Johnson Inno... |
| 29.03.2019 | Inivata Completes $52.6m Series B Funding | Inivata, a Research Triangle Park, NC and Cambridge, UK-based leader in liquid biopsy, completed a Series B fundraising of $52.6m (£39.8m).
Existing investors Woodford Patient Capital Trust, IP Group, Cambridge Innovation Capital and Johnso... |
| 29.03.2019 | Inivata Completes $52.6M Series B Funding Round | Inivata, a leader in liquid biopsy, today announces the completion of a Series B fundraising of $52.6m (£39.8 million).
Existing investors Woodford Patient Capital Trust, IP Group, Cambridge Innovation Capital and Johnson & Johnson Inno... |
| 28.03.2019 | Promising to match more NSCLC patient with targeted drugs, Cambridge spinout Inivata readies US launch of liquid biopsy | This has been a big month for Inivata, the liquid biopsy company spun out from Cancer Research UK and Cambridge University. After securing Medicare coverage for its first blood test — used to profile advanced non-small ce... |
| 28.03.2019 | CIC invests in Inivata’s £40 million series B funding round | CIC invests in Inivata’s £40 million series B funding round
28-03-2019
Cambridge Innovation Capital plc (CIC), the venture capital investor focused on IP-rich technology and life science businesses in the Cambridge ecosystem, has participat... |
| 28.03.2019 | Daily funding roundup - March 28th, 2019 | BillionToOne raised $15M; Polyneuron Pharmaceuticals secured $22.6M;Prevail Therapeutics lands $50M
Artiphon: Artiphon is empowering a new generation to explore music-making with smart instruments and adaptive software. Artiphon has raised ... |
| 28.03.2019 | CIC invests in Inivata’s £40 million series B funding round | Funds will accelerate commercialisation of InVisionFirstTM-Lung Liquid Biopsy test and the development of the InVision® liquid biopsy platform into new indications
Cambridge Innovation Capital has participated in Inivata’s Series B fundrais... |
| 07.03.2019 | Inivata publishes positive results of clinical study for InVision® liquid biopsy test | Inivata, a leader in liquid biopsy, has announced the publication of results of a clinical validation and real-world utility study of its InVision® amplicon-based technology for use in advanced non-small cell lung cancer (NSCLC).
The study ... |
| 05.03.2019 | Inivata receives final Medicare Coverage Determination of InVision-First-Lung | Inivata, a leader in liquid biopsy, has announced that Palmetto GBA, a Medicare Administrative Contractor recognized for its molecular diagnostic technology assessment experience through its assessment group, MolDx, has issued its final Cov... |
| 24.09.2018 | Inivata presents results of prospective clinical validation study of its InVisionFirst-Lung liquid biopsy test | InVisionFirst-Lung testing demonstrates excellent concordance with standard of care tissue profiling and enables more complete profiling of patients with advanced NSCLC
26% more actionable mutations found than standard of care tissue testin... |
| 12.09.2018 | Inivata strengthens senior leadership team | Inivata, a leader in liquid biopsy, has strengthened its senior leadership team with the appointment of Clive Morris, formerly Chief Medical Officer, as Chief Executive Officer, Stacy Chick as Chief Commercial Officer and Thomas Schlumpberg... |
| 19.03.2018 | Inivata publishes results of analytical validation for InVisionFirst-Lung | Industry-leading sensitivity and specificity shown across all classes of genomic alterations relevant to non-small cell lung cancer
Inivata has announced the publication of the analytical validation of its InVisionFirst-Lung targeted advanc... |
| 15.03.2018 | Inivata announces collaboration with MedStar Health | Medstar and the MedStar Georgetown Cancer Institute to join the Inivata Knowledge Accumulation Network (IKAN)
Inivata has announced a collaboration under which MedStar and the MedStar Georgetown Cancer Institute will join the IKAN.
IKAN is ... |
| 01.11.2017 | Inivata announces strategic partnership with West Cancer Center | Inivata has announced a strategic partnership with West Cancer Center that will see the organisation join the Inivata Knowledge Accumulation Network (IKAN).
The IKAN is a global network of world-leading cancer centers working in partnership... |
| 26.10.2017 | Inivata unveils SAB | Inivata has announced the formation of its Scientific Advisory Board (SAB) comprising global experts in oncology and liquid biopsy. The newly appointed SAB will serve as a strategic sounding board and resource as Inivata continues to progre... |
| 17.10.2017 | Inivata highlights new clinical data on InVision™ platform in advanced NSCLC | First data published using amplicon-based technology to detect ALK and ROS1 fusions
Highly sensitive detection of resistance mutations provides basis for optimising therapy for patients with relapsed NSCLC
Inivata announces that new clinica... |
| 13.10.2017 | Inivata and Genomics England to explore potential of liquid biopsy | Pilot study to test Genomics England samples using Inivata’s InVisionTM platform
Inivata is collaborating with Genomics England to assess the quality of blood plasma samples and explore the potential of liquid biopsy to improve disease mana... |
| 27.09.2017 | Addario Lung Cancer Medical Research Institute and Inivata announce major study | InVision™ ctDNA liquid biopsy platform to be used to inform therapy following surgery of curative intent
Addario Lung Cancer Medical Research Institute (ALCMI), a patient founded not-for-profit global research consortium, and Inivata have a... |
| 08.09.2017 | Inivata appoints Dr Jamie Platt as COO | Inivata has announced the appointment of Dr Jamie Platt as Chief Operations Officer. Jamie will be based at Research Triangle Park, NC, and will drive operational excellence across the organisation, including both the UK and the US CLIA lab... |
| 07.09.2017 | Inivata announces strategic partnership with Levine Cancer Institute and formation of IKAN | Inivata has announced a strategic partnership with Carolinas HealthCare System’s Levine Cancer Institute and the subsequent formation of the Inivata Knowledge Accumulation Network (IKAN).
Levine Cancer Institute becomes the founding member ... |
| 02.06.2017 | Inivata Highlights New Clinical Data on the InVision™ ctDNA Liquid Biopsy Platform in advanced NSCLC at ASCO 2017 Annual Meeting | Study shows InVision to be more sensitive than ddPCR and detects competing resistance mutations
Inivata has announced new clinical data, from a collaboration with Dana-Farber Cancer Institute, will be presented at the American Society of Cl... |
| 30.03.2017 | Inivata and Gustave Roussy publish first reported study of clinical outcomes in patients whose treatment was based on ctDNA profiling | Publication in Annals of Oncology shows benefit of osimertinib in EGFR-mutant non-small cell lung cancer patients with T790M-mutation detected by InVisionTM ctDNA liquid biopsy platform.
First reported study of clinical outcomes in patients... |
| 07.12.2016 | Inivata and Gustave Roussy to Present Data at World Lung Conference | Inivata will present data today with collaborators from Gustave Roussy at the 17th World Conference on Lung Cancer in Vienna. The data generated in the joint project explores the clinical benefit for non-small cell lung cancer (NSCLC) patie... |
| 05.12.2016 | Inivata Wins One Nucleus BioNewsRound Award 2016 at Genesis Conference | Inivata has been named as this year’s winner of the One Nucleus BioNewsRound Award, as announced at the Genesis 2016 in London. The award reflects an online vote from peers following the selection of a six-strong shortlist by an expert pane... |
| 03.11.2016 | Inivata and N-of-One to provide personalised genomic interpretation and clinical trial matching | N-of-One to identify treatment strategies and clinical trial opportunities for patients based on Inivata’s ctDNA liquid biopsy analysis
Inivata and N-of-One, Inc., a precision medicine oncology decision support company, are pleased to annou... |
| 12.10.2016 | Inivata launches clinical validation study in non-small cell lung cancer | Inivata has announced the launch of its US clinical validation study (INI-001) in non-small cell lung cancer (NSCLC).
INI-001 will be conducted at more than 30 centers in the US and led by co-principal investigators Ramaswamy Govindan, MD, ... |
| 13.09.2016 | Inivata opens US CLIA laboratory | Inivata has formally announced the establishment of its US site in Research Triangle Park, NC (RTP) with an Open Laboratory reception and visit from Secretary of Commerce John E. Skvarla III. |
| 27.01.2016 | Inivata ‘liquid biopsy’ technology company raises £31.5M | Inivata ‘liquid biopsy’ technology company raises £31.5M
27-01-2016
Clinical cancer genomics company, Inivata, has announced the completion of a Series A fundraising of £31.5 Million, from investors including CIC. The company, a leader in c... |
| 26.01.2016 | Inivata Completes £31.5M Series A Funding | Inivata Limited, a Cambridge, UK-based clinical cancer genomics company employing the precision of circulating tumour DNA analysis to improve personalized healthcare in oncology, completed a £31.5M Series A funding. (approx. $45M).
Backers ... |
| 23.09.2014 | Inivata raises £4m to improve cancer treatment through simple blood tests | Inivata raises £4m to improve cancer treatment through simple blood tests
23-09-2014
Inivata, a clinical cancer genomics company focused on harnessing the potential of circulating tumour DNA (ctDNA) analysis to improve cancer testing and tr... |
| 23.09.2014 | Inivata Raises £4m in Funding | Inivata, a Cambridge, UK-based clinical cancer genomics company, raised £4m in funding.
The round was led by Imperial Innovations with participation from Cambridge Innovation Capital and Johnson & Johnson Development Corporation.
Led by... |
| 23.09.2014 | Inivata raises £4m to realise the potential of ctDNA analysis to improve cancer treatment through simple blood tests | Inivata raises £4m to realise the potential of ctDNA analysis to improve cancer treatment through simple blood tests
New spin-out from Cancer Research UK launched with funding from Imperial Innovations, Cambridge Innovation Capital and John... |
| 23.09.2014 | Inivata raises £4m to improve cancer treatment through simple blood tests | Inivata, a clinical cancer genomics company focused on harnessing the potential of circulating tumour DNA (ctDNA) analysis to improve cancer testing and treatment, today announced it has raised £4m in a funding round led by Imperial Innovat... |
